McMaster Textbook of Internal Medicine

McMaster Textbook of Internal Medicine
Interviews
Cardiology
Tolerance and adverse effects of PCSK9 inhibitors

Tolerance and adverse effects of PCSK9 inhibitors

2017-10-26

Ian Graham

What are the tolerance and adverse effects of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors?

Ian Graham: These are given by injection. There is very little cross-interaction with drugs that are given orally. In general, so far, the side-effect profile of PCSK9 inhibitors has been very satisfactory. Some people get some irritation at the injection site, some people get a flu-like illness, but those are the only real major side effects that have been recorded. There has been just a suggestion of whether cognitive function might be affected but this has not been confirmed. It is something that is being monitored in ongoing trials.

See also

Preparing a patient with cardiovascular disease for major surgery How should we prepare a patient with cardiovascular disease for a major surgery? What diagnostic procedures should we perform? Should we start a new treatment or change the already used drugs or their doses?
Patients requiring immediate blood pressure lowering Does every patient with a BP >180/100 mm Hg require urgent treatment and hospitalization? What antihypertensive agents should be used in general practice? How to quickly lower BP?
Changes in the management of non-ST-segment elevation ACS What has recently changed in the management of non-ST-segment elevation acute coronary syndrome?
Quitting smoking, weight gain, and risk of CV events Smoking cessation often causes weight gain that is difficult to manage. Bearing in mind the risk of cardiovascular events, is it better for a patient to continue smoking or to put on weight?
Acute heart failure: management according to the latest ESC guidelines A lecture by Prof. Piotr Ponikowski, from Wrocław Medical University, Poland, delivered at McMaster International Review Course in Internal Medicine in Kraków in May 2016.
PCSK9 inhibitors in secondary prevention of MI In which patients should proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors be used in the secondary prevention of myocardial infarction (MI)?
Suspicion of familial dyslipidemia In what patients should we suspect familial dyslipidemia?
New lipid-lowering drugs in hypercholesterolemia Which patients with hypercholesterolemia may be offered new lipid-lowering drugs, including proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors?
Treatment of patients with a history of MI after noncardiac surgery Are there any differences in the treatment of patients with myocardial infarction after noncardiac surgery compared to other patients with myocardial infraction? How is the management influenced by a history of coronary artery disease and previous percutaneous coronary intervention?
LDL threshold for starting statins in otherwise healthy patients What is the threshold for low-density lipoprotein cholesterol levels for starting statins in otherwise healthy middle-aged men or women?

We would love to hear from you

Comments, mistakes, suggestions?